Date: 2018-07-23
Type of information: Nomination
Compound: chief operating officer - vice president
Company: Gamida Cells (Israel)
Therapeutic area: Autoimmune diseases – Immunological diseases - Inflammatory diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 23, 2018, Gamida Cell announced the appointments of Tzvi Palash as chief operating officer (COO) and John D. Schick as vice president, market access.
- Mr. Palash brings over 30 years of expertise in commercial operations in the healthcare industry to this new role at Gamida Cell, where he will be responsible for overseeing operational activities. Mr. Palash joins Gamida Cell from Protalix Biotherapeutics, where, as COO, he led all operational activities through the company’s approval by the FDA of plant cell culture produced protein product, Elelyso®. Prior to joining Protalix, Mr. Palash served as a general manager at ColBar LifeScience, a biomaterial company acquired by Johnson & Johnson, where he led the planning, construction, scale-up and regulatory oversight of its Israel-based manufacturing facility. He also successfully led FDA audits for Evolence® and Ossix®, and was a member of the Global Aesthetic Management Team within the Consumer Group of Johnson & Johnson. Earlier in his career, Mr. Palash held operational roles at Teva Pharmaceutical Industries and Interpham Laboratories.
- Mr. Schick will lead the strategic planning and implementation of global market access and reimbursement initiatives. He joins Gamida Cell from Kite Pharma, where he served as senior director, payer relations, and was responsible for the development and implementation of tactical strategies to ensure appropriate access to cancer immunotherapy Yescarta®. Prior to joining Kite, Mr. Schick served as a director at Infinity Pharmaceuticals, where he led the design, implementation and management of trade, distribution and physician network functions to support potential launch of the company’s hematology/oncology candidate. Mr. Schick has also held various roles at Onyx Pharmaceuticals, Otsuka America Pharmaceutical and Allergan.
Financial terms:
Latest news:
Is general: Yes
